Biovertis Overview

  • Founded
  • 2003
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Biovertis General Information


Developer of small-molecule antibacterials. The company focuses on the development of small-molecule antibacterials for treating infections caused by pathogenic bacteria, enabling healthcare professionals to get antibacterial solutions.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Campus Vienna Biocenter 6
  • Vienna, 1030
  • Austria
+43 01 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Biovertis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 23-May-2018 000.00 Completed Generating Revenue
3. Early Stage VC (Series B) 29-Jan-2006 000.00 000.00 Completed Startup
2. Early Stage VC (Series A) 09-Oct-2004 $14.8M $14.8M Completed Startup
1. Grant $6.53M Completed Startup
To view Biovertis’s complete valuation and funding history, request access »

Biovertis Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Kapital & Wert Group Venture Capital Minority 000 0000 000000 0
Kreos Capital Lender/Debt Provider Minority 000 0000 000000 0
Life Sciences Partners Venture Capital Minority 000 0000 000000 0
TVM Capital Life Science Venture Capital Minority 000 0000 000000 0
To view Biovertis’s complete investors history, request access »

Biovertis Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 01-Dec-2005 000000000000000000 Biotechnology 00000 000000
To view Biovertis’s complete acquisitions history, request access »

Biovertis Subsidiaries (1)

Company Name Industry Location Founded
0000000000 Biotechnology Munich, Germany 0000
To view Biovertis’s complete subsidiaries history, request access »